Agomab announces first patient dosed in global Nov-Era Phase 2B study of ontunisertib in fibrostenosing Crohn's disease
AGMB•Agomab said the first patient has been dosed in its global Nov-Era Phase 2B study of ontunisertib, which is expected to enroll about 320 patients.
1. Study begins dosing
Agomab Therapeutics said the first patient has been dosed in its global Nov-Era Phase 2B study of ontunisertib in fibrostenosing Crohn's disease. The study is expected to enroll about 320 patients globally.
